Evaluating a new treatment for metastatic colorectal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study assesses the safety and efficacy of telisotuzumab adizutecan when combined with standard chemotherapy agents like oxaliplatin, fluorouracil, leucovorin, and targeted therapies such as bevacizumab or panitumumab in adults with metastatic colorectal cancer. The trial is structured in two stages, starting with dose escalation to determine the maximum tolerable dose before randomizing participants into treatment arms. The goal is to evaluate adverse events and changes in disease activity associated with this investigational drug.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
* Laboratory values meeting the criteria within the protocol.
* Has measurable disease per response evaluation criteria in solid tumors (RECIST) v1.1.

Exclusion Criteria:

* Prior systemic regimen containing c-Met targeting agent(s) (e.g., antibody, antibody drug conjugate, bispecific) and/or any topoisomerase inhibitor(s) (e.g., irinotecan).
* History of other malignancies within 5 years prior to screening, except for malignancies with a negligible risk of metastasis or death.

Where it's running

• City of Hope National Medical Center /ID# 270255
  Duarte, California, United States Recruiting
• UCLA - Santa Monica /ID# 270621
  Santa Monica, California, United States Recruiting
• Yale New Haven Hospital /ID# 270565
  New Haven, Connecticut, United States Recruiting
• AdventHealth Orlando /ID# 270789
  Orlando, Florida, United States Recruiting
• Northwest Georgia Oncology Centers /ID# 270245
  Marietta, Georgia, United States Recruiting
• University of Chicago Medical Center /ID# 271688
  Chicago, Illinois, United States Recruiting

+32 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Abbvie Call Center
• Email: abbvieclinicaltrials@abbvie.com
• Phone: 844-663-3742

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comparing new treatments for metastatic colorectal cancer with a specific mutation

  This study is testing if a new combination of treatments can help people with a specific type of metastatic colorectal cancer feel better compared to standard treatments.

  Recruiting at 231 sites Phase 3 Amgen · Chandler, Arizona and 290 other locations · NCT06252649

• Comparing two treatments for metastatic colorectal cancer

  This study is testing which combination of treatments works better for people with metastatic colorectal cancer: one with panitumumab or the other with bevacizumab.

  Recruiting Phase 2 Charite University, Berlin, Germany · Berlin · NCT05007132

• Second-line combination treatment for MSS metastatic colorectal cancer

  This trial will try folinic acid plus continuous 5-FU with liposomal irinotecan, sometimes combined with cetuximab or bevacizumab, as a second-line option for adults with MSS metastatic colorectal cancer who progressed on or cannot tolerate oxaliplatin-based therapy.

  Recruiting Phase 2 The First Hospital of Jilin University · Changchun, Jilin · NCT07559760

• Comparing Precem-TcT (with or without bevacizumab) versus trifluridine/tipiracil plus bevacizumab for people with previously treated metastatic colorectal cancer

  This trial will see if Precem-TcT, alone or with bevacizumab, helps people with metastatic colorectal cancer who have already received standard chemotherapy, compared with trifluridine/tipiracil plus bevacizumab.

  Recruiting at 116 sites Phase 3 EMD Serono · San Francisco, California and 115 other locations · NCT07549412

• Telisotuzumab Adizutecan with Bevacizumab vs LONSURF with Bevacizumab in refractory metastatic colorectal cancer

  This study tests whether adding telisotuzumab adizutecan to bevacizumab helps adults with refractory metastatic colorectal cancer more than the standard care of LONSURF plus bevacizumab.

  Recruiting at 88 sites Phase 3 AbbVie · Goodyear, Arizona and 87 other locations · NCT07525206

• Elovie (bevacizumab biosimilar) for metastatic colorectal cancer in Brazil

  This project will see if the biosimilar bevacizumab Elovie works well and is safe for adults in Brazil with unresectable stage IV metastatic colorectal cancer receiving first-line therapy.

  Recruiting at 14 sites Libbs Farmacêutica LTDA · Vitória, Espírito Santo and 13 other locations · NCT06808685

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.